Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC)

87 filings reported holding RVNC - Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q4 2016.
Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) has 79 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 26.1M shares of 105M outstanding shares and own 24.92% of the company stock.
Largest 10 shareholders include Essex Woodlands Health Ventures, Inc. (4.59M shares), JPMORGAN CHASE & CO (3.43M shares), FRANKLIN RESOURCES INC (3.28M shares), WELLINGTON MANAGEMENT GROUP LLP (2.15M shares), Arrowpoint Asset Management, LLC (2.02M shares), Bank of New York Mellon Corp (1.94M shares), BlackRock Fund Advisors (1.4M shares), Polar Capital LLP (1.3M shares), VANGUARD GROUP INC (826K shares), and CANADA PENSION PLAN INVESTMENT BOARD (583K shares).
This table shows the top 79 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.